United Gene High-Tech Group Limited announced the board will inform based on a preliminary review of the unaudited consolidated management accounts of the Group for the six months ended December 31, 2013, the group is expected to record a substantial increase in the consolidated net loss for the six months ended December 31, 2013 as compared with the corresponding period in 2012, due to a loss on the acquisition of the convertible bonds issued by Extrawell Pharmaceutical Holdings Limited.
Innovative Pharmaceutical Biotech Limited
Equities
399
BMG4783W1073
Industrial Machinery & Equipment
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.195 HKD | 0.00% | 0.00% | -10.96% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-10.96% | 43.07M | |
+13.46% | 46.51B | |
+2.04% | 38.25B | |
+13.59% | 7.6B | |
+17.03% | 7.15B | |
-10.35% | 5.19B | |
+14.07% | 1.68B | |
+20.19% | 1.5B | |
-3.21% | 1.31B | |
+22.93% | 1.17B |
- Stock Market
- Equities
- 399 Stock
- News Innovative Pharmaceutical Biotech Limited
- United Gene High-Tech Group Limited Provides Earnings Guidance for the Six Months Ended December 31, 2013